Search results
Results From The WOW.Com Content Network
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead’s products in development act through RNA interference (RNAi) mechanisms of action. [2] [3] The company focuses on treatments for hepatitis B, liver disease associated with alpha 1-antitrypsin deficiency and cardiovascular ...
For premium support please call: 800-290-4726 more ways to reach us
FDA news: Trump administration pauses communication from CDC, other health agencies FDA approval of Journavx comes after 2 drug trials. Journavx was evaluated in two random double-blind ...
The U.S. Food and Drug Administration (FDA) on Thursday approved a new type of prescription pain medication for adults to treat moderate to severe acute pain. The drug, called Journavx ...
This listing is limited to those independent companies and subsidiaries notable enough to have their own articles in Wikipedia. Both going concerns and defunct firms are included, as well as firms that were part of the pharmaceutical industry at some time in their existence, provided they were engaged in the production of human (as opposed to veterinary) therapeutics.
By Steven Brill Letter From the Editors Backstage at Johnson & Johnson. On May 20, about 100 stock analysts gathered in the ballroom of the Hyatt Regency Hotel in New Brunswick, New Jersey, to hear good news from top executives at Johnson & Johnson: The company had 10 new drugs in the pipeline that might achieve more than a billion dollars in annual sales.
AOL latest headlines, entertainment, sports, articles for business, health and world news.
U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated with opioids.